GuoLine Advisory Pte Ltd Purchases 9,940 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GuoLine Advisory Pte Ltd lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,300 shares of the biopharmaceutical company's stock after buying an additional 9,940 shares during the quarter. Regeneron Pharmaceuticals makes up about 3.8% of GuoLine Advisory Pte Ltd's investment portfolio, making the stock its 12th largest position. GuoLine Advisory Pte Ltd owned about 0.05% of Regeneron Pharmaceuticals worth $35,707,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of REGN. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $25,000. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $32,000. Finally, Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on REGN shares. Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Bernstein Bank cut their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. UBS Group cut their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Finally, Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $874.56.

Regeneron Pharmaceuticals Stock Down 18.5%

NASDAQ:REGN traded down $112.15 during mid-day trading on Friday, reaching $493.24. The company's stock had a trading volume of 6,307,887 shares, compared to its average volume of 829,463. Regeneron Pharmaceuticals, Inc. has a 1 year low of $485.00 and a 1 year high of $1,211.20. The stock has a fifty day moving average of $584.25 and a 200-day moving average of $666.47. The firm has a market capitalization of $53.25 billion, a PE ratio of 12.89, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period last year, the company earned $9.55 earnings per share. The firm's revenue was down 3.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.